Characterization and Prediction of Adverse Events from Intensive Chronic Heart Failure Management with and without NT-proBNP Guidance: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study

analyses. Most of the observed costs (78%) and LOS (75%) occurred on the index hospitalization and drove the cumulative results. A similar trend was found even when excluding those who died at the index hospitalization. Conclusion: Patients with transient increases in SCr were more likely to experience longer cumulative LOS and higher costs than those without WRF or WRF which persisted until discharge. Further research is needed to investigate the causes and implications of the markedly prolonged LOS and increased costs associated with WRFt patients.